John Maris
Overview
Explore the profile of John Maris including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
443
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wu C, Huang L, Zhang Z, Ju Z, Song X, Kolb E, et al.
Sci Rep
. 2024 Aug;
14(1):19891.
PMID: 39191826
Osteosarcoma is the most common primary bone malignancy in children and young adults, and it has few treatment options. As a result, there has been little improvement in survival outcomes...
2.
Schoeman S, Bagatell R, Cahill A, Maris J, Mattei P, Mosse Y, et al.
Pediatr Blood Cancer
. 2024 Jan;
71(4):e30887.
PMID: 38291721
Purpose: To determine whether percutaneous core needle biopsy (PCNB) is adequate for the diagnosis and full molecular characterization of newly diagnosed neuroblastoma. Materials And Methods: Patients with newly diagnosed neuroblastoma...
3.
Pearson A, Dubois S, Buenger V, Kieran M, Stegmaier K, Bandopadhayay P, et al.
Eur J Cancer
. 2021 Feb;
146:115-124.
PMID: 33601323
Based on biology and pre-clinical data, bromodomain and extra-terminal (BET) inhibitors have at least three potential roles in paediatric malignancies: NUT (nuclear protein in testis) carcinomas, MYC/MYCN-driven cancers and fusion-driven...
4.
Li Y, Glessner J, Coe B, Li J, Mohebnasab M, Chang X, et al.
Nat Commun
. 2020 Jan;
11(1):255.
PMID: 31937769
Copy number variants (CNVs) are suggested to have a widespread impact on the human genome and phenotypes. To understand the role of CNVs across human diseases, we examine the CNV...
5.
Voeller J, Erbe A, Slowinski J, Rasmussen K, Carlson P, Hoefges A, et al.
J Immunother Cancer
. 2019 Dec;
7(1):344.
PMID: 31810498
Background: Unlike some adult cancers, most pediatric cancers are considered immunologically cold and generally less responsive to immunotherapy. While immunotherapy has already been incorporated into standard of care treatment for...
6.
Testori A, Lasorsa V, Cimmino F, Cantalupo S, Cardinale A, Avitabile M, et al.
Genes (Basel)
. 2019 Sep;
10(9).
PMID: 31480262
In the past years, genome wide association studies (GWAS) have provided evidence that inter-individual susceptibility to diverse pathological conditions can reveal a common genetic architecture. Through the analysis of congenital...
7.
Matthay K, London W, Maris J, Adamson P, Park J
J Clin Oncol
. 2014 Nov;
32(36):4174-5.
PMID: 25403223
No abstract available.
8.
9.
Wilzen A, Krona C, Sveinbjornsson B, Kristiansson E, Dalevi D, Ora I, et al.
Mol Cancer
. 2013 Jul;
12(1):70.
PMID: 23835063
Background: Neuroblastoma (NB) tumours are commonly divided into three cytogenetic subgroups. However, by unsupervised principal components analysis of gene expression profiles we recently identified four distinct subgroups, r1-r4. In the...
10.
Hill-Kayser C, Tochner Z, Both S, Lustig R, Reilly A, Balamuth N, et al.
Pediatr Blood Cancer
. 2013 Jun;
60(10):1606-11.
PMID: 23737005
Background: Proton therapy for treatment for high-risk neuroblastoma may offer sparing of organs at risk (OAR) when compared to intensity-modulated X-ray therapy (IMXT). Procedure: Double-scattered proton plans and IMXT plans...